Breast cancer (advanced & metastatic) - bevacizumab (terminated appraisal)
Bevacizumab for the first-line treatment of metastatic breast cancer
Summary
NICE is unable to recommend the use in the NHS of bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer because no evidence submission was received from the manufacturer or sponsor of the technology.
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA147
Issued: June 2008
How this guidance was produced